Delirium affects 25% of older inpatients and is associated with long-term cognitive impairment and future dementia. However, no population studies have systematically ascertained cognitive function before, cognitive deficits during, and cognitive impairment after delirium. Therefore, there is a need to address the following question: does delirium, and its features (including severity, duration, and presumed aetiologies), predict long-term cognitive impairment, independent of cognitive impairment at baseline?
Background
Delirium is a severe neuropsychiatric syndrome mainly precipitated by acute illness, affecting at least 1 in 8 inpatients in industrialised countries. [1] [2] [3] Symptoms include acute onset of inattention, other cognitive deficits, altered level of consciousness, and psychosis.
[4] Delirium has multiple adverse consequences, including higher mortality, longer hospital stay, and increased institutionalisation. [5] [6] [7] It is also highly distressing for patients, carers and staff. [8] A range of studies have demonstrated that delirium is associated with future long-term cognitive impairment.[9-15] However, these have major methodological limitations, either:
(i) Delirium outcomes have been measured without pre-morbid baseline cognitive assessments, i.e. observed cognitive impairment at follow-up is confounded by undiagnosed pre-existing cognitive impairment (Figure 1, top panel) ; [13, 16] or (ii) Delirium has been retrospectively ascertained, so detailed information on the features any delirium is lacking (Figure 1, middle panel) . [9-12, 14, 15] Thus, a critical gap is that no study has involved all three of the essential elements of (a) determining baseline cognitive function, then (b) ascertaining delirium prospectively, and then (c) assessing delirium's impact on future long-term cognitive impairment. This is the key approach of the current study (Figure 1, bottom panel) .
Prospective ascertainment of delirium is important for several reasons. First, it is less subject to recall bias, which is common in the context of residual cognitive impairment.
Second, prospective ascertainment allows for detailed assessment of the features of delirium. This is crucial because there are wide variations in the features of delirium, including severity, duration, and aetiology. [17] Such variations likely influence the risk of long-term cognitive impairment because delirium features affect other outcomes. [18] [19] [20] [21] Finally, a focus on delirium would make possible the differentiation between its specific impact on cognitive outcomes, as opposed to the cognitive decline described in association with acute hospitalisation in general. [22] [23] [24] To advance our understanding of the relationship between delirium and long-term cognitive impairment, we need to address the following question: does delirium, and its features (including severity, duration, and presumed aetiologies), predict long-term cognitive impairment, independent of cognitive impairment at baseline? designed to investigate directly the needs of adults with cognitive impairment, including those unable to give consent for themselves. To not include such participants introduces bias into the research and leaves clinicians and policy makers with no research data to improve care for older patients unable to give consent and invalidate the study almost entirely. [26] For those lacking capacity, a consultee will be sought. Consultees will be routinely sought for all participants, including those with capacity who give consent for this. Where necessary, this may include the GP acting as a professional consultee in line with Section 32 of the Mental Capacity Act. In many cases, consultees will provide important collateral information and their continued involvement will be encouraged. Capacity can fluctuate during delirium and dementia. Where an event occurs that is part of the study (e.g. hospitalisation), consultees will be sought if the participant is unable to give continued consent as appropriate. Thereby, it is intended that for those individuals who lose capacity at any stage the research will continue to be able to participate under the terms of the Mental Capacity Act 2005.
Data to be collected
All participants undergo a baseline assessment, repeated two years later. Data collection started in March 2017 and end of the follow-up period will be in March 2020. Those admitted to hospital will be seen throughout their admission, usually daily. Participants discharged from hospital, and those deemed to be at high risk for delirium will be contacted every two months by telephone in order to estimate incidence of delirium in the community using the Informant Assessment of Geriatric Delirium [27] and quantify trajectories of recovery after delirium ( Figure 3 ). The data acquired in each setting are summarised in Table 1 .
Community assessments
These are mainly undertaken by telephone, though some participants are seen at home or in the Bloomsbury Centre for Clinical Phenotyping. The whole sample is assessed at baseline and two years later (primary outcome measure). In addition, a 12.5% subsample (n=250) of the most cognitively impaired (highest-risk for delirium) is being proactively monitored by the research team ( Figure 3 ).
The baseline contact comprises:
-Consent for involvement in DELPHIC, specifically including: hospital assessments in the event of acute illness (particularly if capacity is impaired through delirium or dementia at subsequent contacts); record linkage of electronic health data in primary and secondary care -If capacity to consent is impaired, a consultee declaration will be sought, in line with NHS 
Proactive telephone contact for highest risk
Age and baseline cognitive impairment are the strongest risk factors for delirium. A subsample of the 12.5% most cognitively impaired (n=250) ( Table 2) are selected for enhanced delirium surveillance, before and after any hospitalisations ( Figure 3 ). This strategy has previously been used for ascertaining other acute events in population samples, e.g. falls. [32, 33] This allows for the most complete understanding of how delirium develops and patterns of recovery across healthcare settings, thereby challenging the assumption that most delirium presents to acute hospitals.
The research team undertake telephone contacts each day (Monday-Friday), covering the subsample of 250 participants and/or their nominated trusted advisors (consultees) every two months ( Figure 3 ). Each contact has the following purposes: -Assess any new health problem (every two months).
-Assess any delirium symptoms using the validated Informant Interview for Geriatric Delirium ). This provides key information on community delirium both before hospitalisation and tracks recovery after hospital (every two months).
-Repeated TICS-m in participants after discharge (every four months) ( Figure 3 ).
Hospital assessments
Admissions lists are screened Monday-Friday, identifying participants who have been admitted (emergency and elective). Specific audit data from Camden practices, along with reports from NHS Digital, indicate that the admission rate in this age group is up to 20/1000/month. This amounts to 1,000 events over the two year study period, with the highest-risk being admitted recurrently. Participants admitted to UCH or RFH are seen every weekday. Relevant clinical data from out-of-hours (including weekends and participants discharged before assessment) maximise ascertainment using validated method for detecting delirium from medical notes and interviews with ward staff and family.
[35] Hospitalised participants will be followed up at St Pancras Hospital if they are discharged to bed-based rehabilitation. Participants at St Pancras will be seen a minimum of twice a week.
After hospitalisation, participants (and/or proxies) will continue to be proactively contacted as described above. There will be up to five additional occasions for administering TICS-m, adding longitudinal information on trajectories to recovery or persistent delirium ( Figure 3) . Delirium ascertainment is supervised by DD, with difficult cases used for ongoing training and knowledge sharing. Complex cases are adjudicated on a monthly basis with input from specialist old age liaison psychiatry (ES). The final delirium variables (incidence, duration, severity, aetiology) will be derived by an expert consensus panel, blinded to outcome data.
All available inpatient assessments, telephone contacts, electronic hospital and GP records collected for data linkage will be used.
Additional data sources
Participants are asked to consent for access to their NHS medical and social care notes, including data from GP, community mental health, community rehabilitation and social services records throughout the duration of the study. The facility to do this comes from the Camden Integrated Digital Record. Figure 2 shows the expected mortality for hospitalised persons (delirium and nondelirium). [5, 9, 23, 36] Overall mortality in the population aged A clinically significant change in the two-year total TICS-m score would be 6 (out of 50) points for hospitalised delirium patients (change within-person for incident delirium cases) (hypothesis) and 3 points for hospitalised persons without delirium (compared to delirium cases). [23, 24] This effect size is consistent with other studies using this type of primary outcome where incident delirium was associated with change in global cognition scales of 2.5 (out of 28) points (Blessed Information-Memory-Concentration test) [11] and 4 (out of 30)
Statistical methods

Power calculations for hypothesis
The resulting sample size is n=215 to detect the primary outcome (within-person change in the incident delirium group) and n=431 to compare differences between hospitalised participants without delirium. This allows a margin to assess 70% of admissions or a 50% overestimate of delirium cases, and still be sufficiently powered.
Statistical analyses
Outcome: TICS-m score at follow-up
Exposures:
Main exposure: delirium (severity (MDAS scores); duration (days), modelled as a timevarying covariate across the whole study period); aetiology (four categories: infective/inflammatory; metabolic; pharmacological; other) Confounders: baseline: TICS-m score at baseline, age, sex, ethnicity (three categories), education level (three categories); illness severity: APACHE II at admission and daily total
NEWS scores
Analyses -Linear regression, where outcome is TICS-m score at two years, will be used (hypothesis). 14 parameters are proposed, this can be accommodated by a follow-up sample of 1,400.
-Timing of delirium is important and delirium variables will be analysed as time-varying covariates, where this can be considered 'time at risk' for change in TICS-m score. This also allows the effects of recurrent delirium to be assessed and is flexible for differences in time intervals between delirium occurrences and follow-up.
-More detailed analyses of trajectories in relation to repeated TICS-m scores will be possible using random-effects models. [37] -Data missing at random will be treated using multiple imputation.
-Where appropriate, shared parameters models may jointly link random-effects models with survival analyses to account for attrition due to death.
[38]
Patient and public involvement
Patient and public involvement operates through the formation of a PPI group with input throughout the course of the study. The group is drawn from interested persons in Camden, including those involved with the CCG, Age UK, Carers UK, Alzheimer's Society. The PPI group is involved in refining the study documentation (PIS, consent forms), recruitment strategies as well as dissemination of findings. The group meets every four months, where new study questions and modalities of data collection are considered.
Discussion
The DELPHIC study represents an opportunity to characterise prospectively the impact of delirium on long-term cognitive impairment. It will provide a definitive estimate of cumulative incidence of delirium across settings in a whole population. Prospectively linking a community sample with hospitalisations will lead to new knowledge on pathways to longterm cognitive impairment, overcoming the limitations of previous studies in selected samples. DELPHIC also offers an opportunity to explore mechanisms by providing a population framework to nest representative samples testing hypotheses from experimental studies. [39, 40] With respect to other cohort studies, DELPHIC is closely related to CFAS-DECIDE, where the delirium ascertainment protocols were developed in conjunction.
[41] The community assessments have overlap with measures undertaken in the MRC National Survey for Health and Development. [42, 43] In ascertaining both delirium and dementia, DELPHIC will be a contributing cohort to the Dementias Platform UK.
DELPHIC will lead to a resource for insights into the delirium-dementia relationship from its biological underpinnings through to the public health implications. A systematic characterisation of temporal patterns of acute illness, hospitalisation, delirium and cognitive outcomes is urgently required.[44] DELPHIC will also inform how underlying dementia influences the incidence and detection of delirium, by adding empirical data to the clinical uncertainties surrounding delirium superimposed on dementia. [45, 46] By analysing whole population transitions of cognitive function in older people across healthcare settings, DELPHIC will lead to greater understanding of progression of cognitive impairments in ageing. D  a  v  i  s  D  H  ,  B  a  r  n  e  s  L  E  ,  S  t  e  p  h  a  n  B  C  ,  M  a  c  L  u  l  l  i  c  h  A  M  ,  M  e  a  g  h  e  r  D  ,  C  o  p  e  l  a  n  d  J  ,  M  a  t  t  h  e  w  s  F  E  ,  B  r  a  y  n  e  C  ,  F  u  n  c  t  i  o  n  M  R  C  C  ,  A  g  e  i  n  g  S  :   T  h  e  d  e  s  c  r  i  p  t  i  v  e  e  p  i  d  e  m  i  o  l  o  g  y  o  f  d  e  l  i  r  i  u  m   s  y  m  p  t  o  m  s  i  n  a  l  a  r  g  e  p  o  p  u  l  a  t  i  o  n  -b  a  s  e  d  c  o  h  o  r  t  s  t  u  d  y  :  r  e  s  u  l  t  s  f  r  o  m  t  h  e  M  e  d  i  c  a  l   R  e  s  e  a  r  c  h  C  o  u  n  c  i  l  C  o  g  n  i  t  i  v  e  F  u  n  c  t  i  o  n  a  n  d  A  g  e  i  n  g  S  t  u  d  y  (  M  R  C  C  F  A  S  ) . (  1  3  )  :  9  5  0  -9  5  6  .  2  5  .  M  a  t  t  h  e  w  s  F  E  ,  A  r  t  h  u  r  A  ,  B  a  r  n  e  s  L  E  ,  B  o  n  d  J  ,  J  a  g  g  e  r  C  ,  R  o  b  i  n  s  o  n  L  ,  B  r  a  y  n  e  C  :   A  t  w  o  -d  e  c  a  d  e   c  o  m  p  a  r  i  s  o  n  o  f  p  r  e  v  a  l  e  n  c  e  o  f  d  e  m  e  n  t  i  a  i  n  i  n  d  i  v  i  d  u  a  l  s  a  g  e  d  6  5  y  e  a  r  s  a  n  d  o  l  d  e Hospitalised cohorts lack prospective measures of pre-morbid cognition. Middle panel:
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Population cohorts characterise cognition in community, retrospectively ascertaining delirium. Lower panel: A cohort prospectively tracking cognition before, during and after acute illness. 
